文献速递妇女保健

加拿大医生对影响米非司酮药物流产实施因素的看法:一项全国定性研究

Perspectives Among Canadian Physicians on Factors Influencing Implementation of Mifepristone Medical Abortion: A National Qualitative Study.
PubMed 文献 · Ann Fam Med · 2020-01-01

该研究通过对90名加拿大医生及利益相关者进行半结构化访谈,探讨影响米非司酮药物流产服务启动与持续提供的因素。结果显示加拿大卫生部最初对米非司酮的限制阻碍了医生提供该服务,取消限制后实施主要取决于地方和区域流程。参与者普遍认为米非司酮是药物流产的新标准且属于初级保健范围。

要点

  • 加拿大卫生部最初对米非司酮的限制与省级许可标准不一致,限制了患者可及性。
  • 取消限制后,影响实施的因素主要与地方和区域的执行流程相关。
  • 医生普遍认为米非司酮是药物流产的新标准,且属于初级保健实践范围。

核心结论

  • 加拿大卫生部取消米非司酮限制促进了初级保健环境中流产护理的实施。

研究设计与样本

  • 对加拿大全国范围内提供流产服务和不提供服务的医生及卫生系统利益相关者进行一对一半结构化访谈,共90名参与者,包括农村执业者和无流产经验者。
  • 数据收集、主题分析和解释以创新扩散理论为指导。

主要发现

  • 加拿大卫生部最初的限制阻碍了医生提供米非司酮,且与省级许可标准不一致,从而限制了患者可及性。
  • 取消限制后,剩余影响因素主要与地方和区域的实施流程相关。
  • 参与者强烈认为米非司酮是加拿大药物流产的新标准,并属于初级保健实践范围。

临床怎么用

  • 在初级保健环境中提供米非司酮药物流产服务时,应关注地方和区域的实施流程。
  • 医生可将米非司酮视为药物流产的标准治疗并纳入初级保健实践范围。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Access to family planning health services in Canada has been historically inadequate and inequitable. A potential solution appeared when Health Canada approved mifepristone, the gold standard for medical abortion, in July 2015. We sought to investigate the factors that influence successful initiation and ongoing provision of medical abortion services among Canadian health professionals and how these factors relate to abortion policies, systems, and service access throughout Canada. METHODS: We conducted 1-on-1 semistructured interviews with a national sample of abortion-providing and nonproviding physicians and health system stakeholders in Canadian health care settings. Our data collection, thematic analysis, and interpretation were guided by Diffusion of Innovation theory. RESULTS: We conducted interviews with 90 participants including rural practitioners and those with no previous abortion experience. In the course of our study, Health Canada removed mifepristone restrictions. Our results suggest that Health Canada's initial restrictions discouraged physicians from providing mifepristone and were inconsistent with provincial licensing standards, thereby limiting patient access. Once deregulated, remaining factors were primarily related to local and regional implementation processes. Participants held strong perceptions that mifepristone was the new standard of care for medical abortion in Canada and within the scope of primary care practice. CONCLUSION: Health Canada's removal of mifepristone restrictions facilitated the implementation of abortion care in the primary care setting. Our results are unique because Canada is the first country to facilitate provision of medical abortion in primary care via evidence-based deregulation of mifepristone.

来源:Ann Fam Med,查看原文。版权归原作者所有。

引用

  1. Munro S, Guilbert E, Wagner MS, et al. Perspectives Among Canadian Physicians on Factors Influencing Implementation of Mifepristone Medical Abortion: A National Qualitative Study. Ann Fam Med. 2020. PMID: 32928757. doi:10.1370/afm.2562

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。